Skip to main content
Equibles
XGN logo

XGN · Exagen Inc. · Webcasts, Transcripts & Audio

Track XGN — free

Use XGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.78 +0.31 (+4.15%) At close · Oct 27 Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$187.63M
Shares
24.23M
Volume · Oct 27 180.72K Avg daily vol (3M) 357.75K

Exagen Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Exagen Inc. (XGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-10
Exagen Inc. (XGN) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-08-11
Exagen Inc. (XGN) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Confident tone Revenue and volume growth ASP and revenue cycle management Sales force and commercial expansion
Revenue
$19.94M
▲ 15.9% YoY
Diluted EPS
$-0.13
Gross margin
61.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Confident tone ASP and revenue cycle execution Myositis pipeline and product cadence Profitability and adjusted EBITDA
Revenue
$17.31M
▲ 11.7% YoY
Diluted EPS
$-0.17
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
Exagen Inc. (XGN) Q4 2025 Earnings Call
Revenue
$16.63M*
▲ 21.8% YoY
Gross margin
55.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Positive tone Average Selling Price (ASP) trajectory Rheumatoid arthritis biomarker launches (anti-PAD4, RA33) Revenue cycle, appeals and payer education
Revenue
$17.24M
▲ 37.9% YoY
Diluted EPS
$-0.31
Gross margin
58.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Confident tone Reimbursement and ASP Improvement Novel Biomarker Launches and Pipeline Clinical Utility and Patient Impact
Revenue
$17.20M
▲ 14.2% YoY
Diluted EPS
$-0.21
Gross margin
60.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
Confident tone ASP and reimbursement progress New biomarker launch and AVISE CTD momentum Operational turnaround and culture
Revenue
$15.50M
▲ 7.5% YoY
Diluted EPS
$-0.20
Gross margin
58.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Positive tone Clinical case studies and physician adoption New biomarker launch (T cell and RA33) Revenue and ASP growth
Revenue
$13.65M*
▼ 0.8% YoY
Gross margin
62.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-21
Exagen Inc. (XGN) Q3 2024 Earnings Call Transcript
Confident tone Revenue and ASP performance Path to profitability and cash flow positivity ACR conference and clinical evidence
Revenue
$12.51M
▼ 6.8% YoY
Diluted EPS
$-0.28
Gross margin
55.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Exagen Inc. (XGN) Q2 2024 Earnings Call Transcript
Confident tone Profitability path and adjusted EBITDA improvement AVISE CTD volume and ASP growth Executive leadership transition
Revenue
$15.06M
▲ 6.6% YoY
Diluted EPS
$-0.16
Gross margin
60.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Exagen Inc. (XGN) Q1 2024 Earnings Call Transcript
Confident tone AVISE CTD product enhancements and new markers Volume recovery and ordering efficiencies Expense management and guidance caution
Revenue
$14.41M
▲ 28.4% YoY
Diluted EPS
$-0.19
Gross margin
59.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
Confident tone AVISE CTD Core Product Performance Average Selling Price (ASP) Improvement Path to Profitability and Cashflow Breakeven
Revenue
$13.77M*
▲ 7.2% YoY
Gross margin
59.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript
Revenue
$13.42M
▼ 8.9% YoY
Diluted EPS
$-0.31
Gross margin
57.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript
Revenue
$14.14M
▲ 85.9% YoY
Diluted EPS
$-0.28
Gross margin
58.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript
Revenue
$11.23M
▲ 8% YoY
Diluted EPS
$-0.44
Gross margin
47.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript
Revenue
$12.84M*
▲ 1.2% YoY
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Exagen Inc. (XGN) Q3 2022 Earnings Call Transcript
Revenue
$14.73M
▲ 20.2% YoY
Diluted EPS
$-0.47
Gross margin
59.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript
Revenue
$7.61M
▼ 40.4% YoY
Diluted EPS
$-0.86
Gross margin
20.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Exagen Inc. (XGN) Q1 2022 Earnings Call Transcript
Revenue
$10.39M
▼ 1.8% YoY
Diluted EPS
$-0.60
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Exagen Inc. (XGN) Q4 2021 Earnings Call
Revenue
$12.69M*
▼ 45.9% YoY
Gross margin
61.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Exagen Inc. (XGN) Q3 2021 Earnings Call
Revenue
$12.25M
Diluted EPS
$-0.42
Gross margin
55.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Exagen Inc. (XGN) Q2 2021 Earnings Call
Revenue
$12.77M
▲ 42.7% YoY
Diluted EPS
$-0.38
Gross margin
57.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Exagen Inc. (XGN) Q1 2021 Earnings Call
Revenue
$10.59M
▲ 10.5% YoY
Diluted EPS
$-0.48
Gross margin
55.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Exagen Inc. (XGN) Q4 2020 Earnings Call
Revenue
$23.44M*
▲ 129.5% YoY
Gross margin
81.5%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Exagen Inc. (XGN) Q3 2020 Earnings Call
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.34
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Exagen Inc. (XGN) Q2 2020 Earnings Call
Revenue
$8.95M
▼ 14.6% YoY
Diluted EPS
$-0.27
Gross margin
62.7%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Exagen Inc. (XGN) Q1 2020 Earnings Call
Revenue
$9.58M
▲ 3.5% YoY
Gross margin
52.6%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Exagen Inc. (XGN) Q4 2019 Earnings Call
Revenue
$10.21M*
Gross margin
12.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 webcasts
Key facts CIK 1274737 CUSIP 30068X103 13F (30d) 3 filings 3 filers Visit website Investor relations